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Review
Drug detection in oral fluid specimens was used 
for the first time in the late 1970s, for the pur�
pose of therapeutic drug monitoring [1]. Since 
then, oral fluid ana lysis has increased enor�
mously, as can be seen by the increase in the 
number of publications on this matter over the 
past few years. This coincided with the develop�
ment of more sensitive and reliable analytical 
equipment. �owever, these advances in tech�
nological resources were not solely responsible 
for this situation, as will be discussed further. 
Indeed, the unique properties of oral fluid and its 
advantages over other biological matrices played 
a very important role. 
Advantages of oral fluid testing include the 
fact that the sample is collected noninvasively 
under direct supervision and without loss of 
privacy, reducing the risk of an invalid speci�
men being provided or sample adulteration and/
or substitution [2]. Furthermore, it is thought 
that saliva drug concentrations can be related 
to free drug concentrations in plasma and, 
consequently, to the pharmacological effects of 
drugs [3].
On the other hand, drugs that are ingested 
orally, as well as those that can be smoked, may 
be detected in high concentrations in oral fluid 
following recent use, due to residual amounts 
of drug remaining in the oral cavity [4–8]. 
Therefore, results for these substances may not 
be accurate because the drug concentration 
found in the oral fluid may not reflect the blood 
drug concentration.
Another important disadvantage of study�
ing oral fluid is that examinees are sometimes 
unable to produce sufficient amounts of material 
for ana lysis [2].
For a better understanding of the increas�
ing importance of this biological specimen on 
bioana lysis, as well as the need for sensitive 
techniques, this review will briefly discuss oral 
fluid physiology and the underlying mecha�
nisms of drug incorporation. In addition, col�
lection devices, detected substances and fields of 
application will be reviewed. Finally, the avail�
able analytical techniques for drug detection in 
oral fluid will be outlined, since their application 
represents the main goal of this paper.
Physiology & mechanisms of 
drug incorporation
The terms oral fluid and saliva are often used in 
an interchangeable manner to designate the same 
biological specimen. �owever, oral fluid is the 
liquid sample obtained from the oral cavity, and 
constitutes a number of secretions from several 
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specimen, extremely useful 
for the assessment of  
drug-impaired driving
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sources [8], including saliva. In fact, three pairs 
of major salivary glands (parotid, submaxillary 
and sublingual), as well as an estimated 450–750 
minor accessory salivary glands (situated on the 
tongue, the buccal mucosae and the palate) and 
oro�naso�pharyngeal secretions, contribute to 
some extent to its production. Therefore, oral 
fluid is generally accepted as a more accurate 
definition of this mixture of fluids [9].
Oral fluid contains the same electrolytes 
that are present in other body fluids, includ�
ing water (99%) and mineral salts. Proteins 
(mucins) and some enzymes for digestion are 
also present, but at very low levels. This sample 
is hypotonic compared with serum, although 
its ionic concentrations are not constant due to 
the circadian rhythm.
The p� of oral fluid is approximately 6.8, but 
it can be higher in the case of an increase in the 
salivary flow. In this situation, its p� can even 
be greater than that of plasma [10].
An adult can produce as much as 1000 ml 
oral fluid per day, and typical flows are approxi�
mately 0.05 ml/min while sleeping, 0.5 ml/min 
while spitting and up to 3 ml/min while chewing 
gum [11]. This flow rate may be influenced by 
several factors, including the individual’s emo�
tional state, pregnancy or menopausal�related 
hormonal changes, or by the use of drugs [9].
One common feature when collecting oral 
fluid samples is the so�called ‘dry mouth syn�
drome’. This can be due not only to the anxiety 
provoked by the collection procedure, but also to 
a lack of proper hydration by the examinee [12]. 
Furthermore, the use of anti�adrenergic and 
anticholinergic drugs, or even of illicit drugs 
such as opiates, amphetamines and cannabis [9], 
may also contribute to this syndrome. 
Different mechanisms for drug incorporation 
are thought to occur: passive diffusion through 
the membrane, active processes against a concen�
tration gradient, filtration through pores in the 
membrane and pinocytosis [3,13]. Nevertheless, 
most drugs appear to be incorporated by a 
simple passive diffusion process that depends 
on their physicochemical properties (e.g., pKa 
and molecular weight), the degree of binding to 
plasma proteins and the p� of both blood and 
oral fluid [9,14].
Therefore, nonionized lipophilic drugs can 
easily cross the barrier between plasma and 
saliva, and their concentration in the latter is 
dependent on the nonprotein�bound plasma 
concentration. The low concentrations of 
diazepam and other benzodiazepines usually 
seen in this specimen represent a valid example 
of this dependence, since these compounds are 
highly protein bound [15,16]. 
Drugs that are basic in nature, such as 
amphetamines, cocaine and opiates, gener�
ally have higher concentrations in oral fluid 
than in blood, whereas acidic drugs have much 
lower concentrations. The concentrations of 
D9�tetrahydrocannabinol (T�C) in this specimen 
are more variable in oral fluid than in blood [4], 
possibly due to the deposition of T�C in the 
oral cavity. Furthermore, current belief is that the 
majority of T�C found in oral fluid originates 
from this depot of active T�C [6], since little 
T�C is secreted into saliva [17]. �owever, this 
effect is also seen for other drugs, such as nicotine 
after tobacco smoking and buprenorphine after 
sublingual administration [12].
The p� of oral fluid plays an important role 
in the case of weakly basic drugs, and can greatly 
affect their salivary concentrations. Indeed, 
those drugs whose pKa is close to the saliva’s 
p� will have their degree of ionization dramat�
ically altered with p� changes, and this will 
be reflected in their saliva�to�plasma ratio [10]. 
This influence of the salivary p� on the saliva�
to�plasma ratio of several drugs is perhaps the 
reason why ratios determined experimentally 
differ from theoretical values calculated from 
the �enderson–�asselbach equation [3,18].
On the other hand, with an increase in the 
flow rate, the composition of the specimen will 
change, including its p�, and therefore the 
circumstances of the collection can affect the 
production of oral fluid, which in turn will also 
change the drug content [8]. For this reason, the 
protocol for saliva collection can differ depending 
on the study (with or without stimulation) and 
may be highly important for the determination 
of saliva�to�plasma ratios [10].
�owever, care should be taken in the estab�
lishment of these ratios, since significant intra� 
and inter�individual differences exist, which have 
been discussed elsewhere [19–25]. Nevertheless, 
these differences are not so large in the case of 
alcohol and antiepileptic drugs [22,25].
The research concerning oral fluid ana lysis in 
the case of alcohol consumption has been reviewed 
by Drummer [12], and the oral fluid�to�plasma 
concentration of this drug is similar to that pre�
dicted based on the water content of the two fluids, 
and has been used to assess alcohol exposure.
One important feature regarding oral 
fluid ana lysis is that, contrary to what hap�
pens when other biological specimens such as 
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blood or urine are analyzed, the parent drug 
is the main compound detected, rather than 
its metabolites. 
It should be noted, however, that there is 
the possibility of passive contamination in this 
type of ana lysis. This can occur mainly at two 
levels: by exposure to an environment where 
drugs are being consumed by others (e.g., expo�
sure to cannabis smoke) [26] and by contami�
nation from drugs taken orally, meaning that 
the detected drugs may not proceed from the 
bloodstream. Therefore, this possibility should 
be taken into account in the interpretation of 
the obtained results.
Collection procedures & devices
There are two major advantages of oral fluid test�
ing. First, as discussed above, drug concentrations 
in this specimen can be related to plasma free 
drug concentrations and, consequently, to the 
pharmacological effects of drugs. Second, saliva 
collection is made in a noninvasive and simple 
manner (under close observation, if necessary), 
without infringing on the examinee’s privacy. 
This latter characteristic makes on�site specimen 
collection easy to perform, which is advantageous 
in the assessment of drug�impaired driving situ�
ations. Furthermore, the collection of this speci�
men is less liable to adulteration or substitution in 
comparison with urine sampling [27–29]. 
A variety of methods are available for oral 
fluid collection, with or without stimulation, 
and these include spiting, draining, suction and 
collection on various types of absorbent mate�
rial. �owever, care should be taken since the 
concentration of the drugs can be affected by 
the collection procedure used.
Several techniques may be used to collect stim�
ulated saliva, the simplest of which involves move�
ments of the tongue, cheek or lip, without any 
external stimulus [30,31]. On the other hand, this 
stimulation can be made mechanically by chew�
ing a variety of materials, such as paraffin wax, 
Parafilm®, teflon, rubber bands or gum base [13,32]. 
Likewise, a lemon juice drop or citric acid can be 
placed in the mouth to provide a gustatory stimu�
lus for saliva production [11,30,32,33]. Following this 
stimulation, saliva can then be spat, suctioned, 
absorbed or swabbed for collection [33].
This production stimulation may present 
several problems capable of compromising the 
accuracy of the test, however. For instance, there 
are some drugs and/or metabolites that can be 
absorbed by Parafilm, and paraffin contains 
compounds that may affect chromatographic 
ana lysis [34]. Furthermore, it is possible that the 
salivary composition is changed by the stimula�
tion process, thereby potentially affecting drug 
concentrations in oral fluid [13,35]. In addition, 
citric acid changes saliva p�, which may alter 
drug concentrations in this specimen, and has also 
been shown to alter immunoassay drug test results 
[30,32]. In fact, acidic stimulation has been shown 
to lower codeine [29,36], methamphetamine [37] and 
cocaine [38] concentrations in oral fluid. 
Nonstimulated saliva can be collected by the 
draining method, which is performed by allow�
ing saliva to drip from the mouth into a col�
lection container [33], or can be easily obtained 
by spitting, providing a neat sample. �owever, 
this is relatively viscous and less easily pipetted 
than, for instance, urine, and its collection can 
pose potential occupational health and safety 
problems. In addition, and because it may also 
be contaminated with food, it may not provide 
a fluid of uniform concentration.
Therefore, the sample is typically collected using 
an absorbent pad/foam, which is subsequently 
squeezed or mixed into a diluent (usually buffer) 
to extract the oral fluid and provide a less�viscous 
and easier�to�analyze specimen. Some devices have 
a volume indicator, showing if sufficient oral fluid 
has already been collected [29,36]. 
�owever, the collected sample volume will 
often be less than 1 ml and, therefore, sophis�
ticated and sensitive detection techniques are 
mandatory to achieve the desired sensitivity, as 
will be further discussed.
The advantages and drawbacks of sev�
eral collection devices have been extensively 
reviewed [39,40].
One of the problems that used to be associated 
with these collection devices was that the actual 
volume of sample was not accurately known. This 
has been overcome by the use of a volume ade�
quacy indicator in the collection pad. This makes 
the collected volume well known, improving the 
accuracy of the measurements in this specimen. 
Indeed, for example, the Quantisal™ device’s 
indicator turns blue when a sample volume of 
1 ml (±10%) is collected [201].
Variable collection and recovery volumes 
between different devices may cause quantita�
tive differences if it is assumed that: 
n	A consistent volume is collected 
n	A consistent volume is recovered from the device
n	A consistent amount of drug is recovered from 
the device
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This latter issue is important, since it is well 
known that analyte recovery from the collec�
tion device is concentration dependent and this 
assumes particular relevance at low concentra�
tions. For this reason, the evaluation of each 
device’s performance in terms of analyte recov�
ery should be targeted at a screening assay cut�off 
or a relevant physiological concentration.
Another approach to overcome the variability 
of collected volumes may be the weighing of 
the collection devices before and after sample 
collection [41].
A variety of devices for oral fluid testing 
are commercially available, such as Omni�
Sal® (Cozart Biosciences Ltd, Abingdon, 
UK), Salivette® (Sarstedt AG, Rommelsdorf, 
Germany), Intercept® (OraSure Technologies, 
Bethlehem, PA, USA) and Quantisal™ 
(Immunalysis Corporation, Pomona, CA, 
USA). These devices usually consist of a sor�
bent material that becomes saturated in the 
mouth of the donor, and the oral fluid is recov�
ered by centrifugation or by applying pressure 
[42,43]. The device is often placed in a container 
that contains a stabilizing buffer solution [44]. 
These buffer solutions are not the same for all 
the devices that use this type of approach, and 
this is why these devices show differences in 
their performance, for example concerning 
drug recovery. The acceptability of sample 
collection devices is determined both by the 
speed of collection and ease of handling, and 
the referred devices all have their advantages 
and drawbacks. In addition, attention should 
be paid to the devices’ performance, as some 
collectors have been shown to absorb drug(s) 
irreversibly, meaning that the drugs are not 
able to leach out into the postcollection buffer, 
impairing the accuracy of quantitative ana lysis. 
Several studies have been made on this issue, 
and it appears that drugs are not affected to the 
same extent. Some studies have even obtained 
contradictory results.
Indeed, in one study, a recovery of codeine 
from the Salivette device of more than 80% was 
reported [36,45]; while, in another study, lower 
recoveries (39–42%) were found [29,39]. On the 
other hand, only approximately 38% of T�C 
is recovered from the Intercept device, whereas 
recoveries of 3,4�methylenedioxymethamphet�
amine (MDMA), cocaine, morphine, codeine, 
diazepam and alprazolam from the same device 
are much higher [39]. Moreover, the Cozart® col�
lector shows good recovery for T�C [36,46,47] and 
methamphetamine [37,48] .
Significant differences in drug recoveries from 
the sampling material are reported in the litera�
ture, and these will also lead to variations in the 
measured concentrations in oral fluid. 
Several solutions are proposed to overcome 
this problem. For instance, a modification of the 
sampling procedure for the Intercept collector, 
which consisted of the addition of methanol to 
the elution buffer, resulted in complete recovery 
of T�C over a large concentration range [41]. 
Other studies were conducted on the recovery 
of other drugs from the same device [49,50], and 
significant losses for 7�aminoclonazepam and 
lysergic acid diethylamide (LSD) were found. 
Another study, by Quintela et al. [48], evaluated 
the in vitro performance of the Quantisal device 
for amphetamine, methamphetamine, mor�
phine, codeine, cocaine, benzoylecgonine (BE), 
methadone, oxazepam and T�C. In general, 
recoveries were higher than 90%, but lower for 
BE (82%). 
For T�C, however, high recovery was obtained 
(81.3–91.4%). Other previous studies, using 
Salivette, showed that significant amounts of the 
drugs remained entrapped on the device [51–53].
Another important feature that should be 
taken into account in oral fluid ana lysis is drug 
stability or, more accurately, drug instability in 
the matrix, which can affect the utility of the 
collection process [40]. The inherent chemical 
instability of drugs may be exacerbated in oral 
fluid by the collection device and/or buffer. This 
issue is of utmost importance in oral fluid ana�
lysis, together with analyte recovery from the 
collection device, because drug concentrations 
are generally low in this specimen and, therefore, 
the detectability of the drug may be limited [8]. 
Stability of several analytes, such as T�C, 
morphine, 6�acetylmorphine (MAM), BE and 
designer amphetamines, was evaluated in oral 
fluid samples after collection and was extensively 
discussed [29,48,54–57].
The stability of analytes can be affected by a 
number of conditions, including the use of pre�
servatives in the case of flunitrazepam [58] and 
storage temperature and duration in the case of 
MAM [59] or T�C [29]. 
In conclusion, no type of collection device is 
clearly superior based on design or ease of use. 
On the other hand, the recovery studies con�
ducted on some devices do suggest that drug 
desorption may limit the usability of some col�
lection materials. Therefore, more information 
is required for all drugs likely to be measured in 
oral fluid, and for each collection device.
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Applicability of oral fluid ana lysis
Oral fluid can be used to assess an individual’s 
exposure to virtually every class of compounds, 
but drugs of abuse are by far the most detected 
substances. This is mainly due to the deleterious 
consequences of these substances’ misuse, both 
in workplace medicine and motor vehicle driv�
ing. For this reason, scientific literature is prolific 
in analytical techniques aimed at detecting and 
quantitating a variety of classes of abused drugs, 
namely opiates [52,60–65], cannabinoids [54,66–71], 
amphetamines [21,55,72–77], cocaine [78,79] and 
benzodiazepines [58,80–87]. Other substances 
such as ketamine, g�hydroxybutyrate (G�B) 
[88,89], antibiotics [90], analgesics [91,92], antitus�
sives [93], cyanides and other tobacco compounds 
[94–96], and sildenafil [97], have also been ana�
lyzed. Oral fluid has additional relevance in 
the case of opiate testing, since high amounts 
of 6�monoacetylmorphine can be detected in 
oral fluid in the case of heroin consumption, as 
well as detectable amounts of heroin itself, and 
therefore heroin abuse can be easily detected [12].
Oral fluid presents a wide field of analytical 
applications that take advantage of the afore�
mentioned advantages [2] concerning, for exam�
ple, therapeutic drug monitoring [1,25,45,80,98,99], 
pharmacokinetic studies [4,5,19,37,100], workplace 
medicine [27,101,102] or even detection of illicit 
drugs in driving situations [47,103–112].
The application of oral fluid ana lysis to assess 
drug prevalence is definitely desired, and a posi�
tive correlation to impairment has already been 
shown [106,113]. �owever, it should be pointed 
out that, for most substances, a measured oral 
fluid concentration cannot be used to predict 
the corresponding plasma concentration, due 
to the intra� and inter�individual differences 
discussed earlier. 
Nevertheless, the assessment of drug�impaired 
driving is one of the most impacting applications 
of oral fluid testing, which has contributed to 
the development of several collection materials 
for laboratorial ana lysis and collection devices 
designated for on�site applications. 
Analytical technologies
Due to developments in technology, it is possible 
to detect and quantitate drugs in biological spec�
imens at levels that were unreachable a few years 
ago. As discussed earlier, one of the main disad�
vantages of oral fluid is the fact that one must be 
able to detect very small amounts of drugs, due 
both to their low concentration in this specimen 
and to the fact that usually there is little sample 
available for ana lysis (often less than 1 ml). This 
latter drawback may be manageable by the use of 
multianalyte methods, providing the optimiza�
tion of sample volume and eventually of con�
firmation ana lysis, if necessary. Therefore, the 
development of this type of method is highly 
desirable for oral fluid drug testing. For instance, 
Gunnar et al. have published a method by gas 
chromatography (GS)–mass spectroscopy (MS) 
that is capable of determining 30 derivatized 
drugs in 250 µl of oral fluid [49]. A few LC–MS/
MS multianalyte methods have also been pub�
lished, allowing the simultaneous determina�
tion of several abused drugs [50,114,115], benzodi�
azepines and hypnotics [50,115]. A method for the 
simultaneous determination of 49 substances, 
including some antipsychotics and antidepres�
sants, has also been published [116]. Therefore, 
sensitive and selective techniques are manda�
tory to achieve the desired low levels. The main 
analytical techniques usable for drug detection, 
including their advantages and drawbacks and 
the main parameters that can affect the ana�
lysis, will now be discussed, in light of existing 
literature on the matter.
	n On-site collection devices
The increased use of illegal drugs gave rise to the 
need for quick and reliable methods, which have 
been developed and improved since the 1990s [103], 
for the fast screening of drugged drivers. 
Portable devices have been developed for 
drug detection in several biological f luids, 
namely urine, oral fluid and sweat. The perfor�
mance of various urine on�site screening tests 
has been evaluated [117,118]. �owever, as stated 
previously, oral fluid concentrations of drugs 
can be related to their plasma concentrations 
and, therefore, to the pharmacological state of 
the individual [119,120], while drug detection in 
urine does not necessarily mean that the indi�
vidual was influenced at that specific time [121]. 
Therefore, and due to the ease of its collection, 
oral fluid seems to be a better sample for this 
purpose compared with urine.
One advantage of these portable devices is 
that they allow the initial testing for drugs to 
be easily carried out in the field. A preliminary 
drug test result is usually provided within a few 
minutes, without the need for sophisticated and/
or expensive laboratory equipment. Indeed, easy�
to�use instruments are available that provide an 
electronic readout (e.g., Dräger DrugTest® 
and Orasure Uplink®, Cozart Rapiscan® and 
Drugread® hand photometer), while others 
dRugs Of abuse
Most publications concerning 
oral fluid analysis aim at 
detecting these substances
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require visual identification (e.g., DrugWipe®, 
iScreen OFD™, OralScreen®, Oratect® and 
SalivaScreen™) [2]. On�site collection kits may 
also provide an indirect aid to traffic control, since 
the tested individual is more likely to admit drug 
use after a positive test result. On the other hand, 
individuals under the influence of drugs may be 
deterred from driving, since people are starting 
to become aware that traffic control police are 
able to perform screening tests for drug use [103].
�owever, the assessment of these devices’ per�
formance is not objective, because, for most, the 
specifications are not consistent [2] and details 
concerning the detectability conditions are often 
missing. On the other hand, the ease of use of 
the devices should also be evaluated, taking into 
consideration the opinion of traffic regulation 
officers, since they are the ones who will be using 
them in the field. 
The possibility of supervision of the sampling 
process is especially important in terms of law 
enforcement, since sample adulteration is avoided 
and the possibility of substitution or contamina�
tion appears to be minimal. For these reasons, 
the significance of oral fluid as a primary matrix 
in roadside testing can hardly be questioned. 
Indeed, oral fluid testing has revealed its use�
fulness in detecting drugs of abuse in various 
studies using several devices [46,106,122–130], and it 
can be seen as a good substitute for whole�blood 
samples [128], unless a quantitative ana lysis of 
blood levels is desired. 
The advantages of on�site testing are rapid 
turnaround times, reduced costs and the fact 
that the test can be carried out virtually any�
where [129]. �owever, this type of technology 
presents some problems relating to T�C detec�
tion, since the removal of the drug from the 
collection pad is difficult [67,130].
The scourge of driving under the influence 
of drugs or alcohol is responsible for thousands 
of accidents every year, and up to 25% of them 
involve drivers who tested positive for drugs [131]. 
For instance, in a roadside study by Samyn et al., 
blood ana lysis of drivers suspected of impair�
ment revealed the presence of MDMA in 35% 
of cases; in addition, amphetamine, cocaine and 
cannabis were detected in many of these [104].
The deleterious consequences of drug�
impaired driving on road safety led the European 
Commission to promote scientific studies based 
on oral fluid ana lysis.
The first of these studies was the Roadside 
Testing Assessment (ROSITA), aimed at assess�
ing the value of on�site tests at the roadside, and 
also to give recommendations for the use of 
roadside testing equipment in European coun�
tries. Police officers from 16 countries were sur�
veyed, and saliva was shown to be the preferred 
matrix for drug testing. The reasons for such a 
choice are quite obvious, namely its ready avail�
ability, low invasiveness and good correlation 
with impairment. Test configuration was also 
evaluated in this survey, and the ideal would 
be a single�use multianalyte test able to provide 
a clear and unambiguous test result within a 
5�min interval [103,202]. A collaborative study 
between the USA and the European Union 
(ROSITA�2) has been conducted both to assess 
illegal drug use among motor vehicle operators 
and to evaluate the effectiveness of on�site oral 
fluid drug�detection technologies. Within the 
scope of this study, which was completed in 
2005, Crouch et al. have tested the laboratorial 
performance of ten different devices, namely 
concerning their ability to meet the manufac�
turers’ claimed cut�off concentrations for several 
drug classes, including amphetamines, cocaine 
and metabolites, opiates and cannabinoids [132]. 
Two devices were also evaluated for benzodiaz�
epines. The devices’ results were compared with 
laboratory�based immunoassay and MS results, 
both in terms of sensitivity and specificity.
Another study is ongoing in Europe, the 
Integrated Project Driving under the Influence 
of Drugs, Alcohol and Medicines (DRUID), 
which involves more than 20 European coun�
tries. The objective of this study is to gain new 
insights to the real degree of impairment caused 
by psychoactive drugs and their actual impact 
on road safety, giving scientific support to the 
EU transport policy to establish guidelines and 
measures to combat impaired driving [203].
A study has been conducted in the US (Pilot 
Test of New Roadside Survey Methodology for 
Impaired Driving), aimed at developing and test�
ing new procedures for the assessment of impaired 
driving. In this study, oral fluid samples of over 
600 randomly selected drivers were collected 
and analyzed, and blood was also collected in 
approximately half of those subjects. Several drug 
classes were included in this study, including both 
abused and prescription drugs [204].
	n Immunoassays
In recent years, extraordinary advances in ana�
lytical techniques have enabled the detection of 
drugs and metabolites in alternative specimens. 
The strategy for drug testing in biological flu�
ids (e.g., urine, blood and oral fluid) usually 
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begins with screening procedures, which should 
be able to detect or exclude a drug class and 
elude false�negative results [3]. This is extremely 
useful, especially for those laboratories that are 
required to analyze a large number of samples 
routinely, saving time and money that would be 
wasted in more expensive confirmatory methods 
(usually MS�based techniques), while most of 
the samples would be negative.
Four interpretations are possible following a 
drug test: 
n	True�positive, when the test correctly detects 
a drug in the analyzed specimen
n	False�positive, when the test incorrectly 
detects the presence of a drug where no drug 
is present
n	True�negative, if the test correctly confirms 
the absence of a drug
n	False�negative, when the test fails to detect a 
drug that is actually present in the sample 
A test’s sensitivity is determined by its ability 
to detect the presence of a drug at or above a 
cut�off level [133].
For obvious reasons, to choose this cut�off 
level one must optimize the number of true�
positive and true�negative samples, and the 
number of false�positives and false�negatives 
should be kept to a minimum. Indeed, if the 
cut�off is set too low, the number of false�
positive samples will be too high and there 
will be an unnecessary high number of con�
firmation analyses, as stated previously. On 
the other hand, a cut�off value that is too high 
will lead to a large number of false�negative 
samples, impairing the test’s usefulness in its 
applications, namely in the clinical and forensic 
fields [44]. �owever, this is not an easy task, 
since these tests are designed for maximum 
sensitivity, in order to minimize the possibility 
of a false�negative sample, which increases the 
probability of obtaining a false�positive result.
Another common characteristic of immu�
noassays is their specificity or, more accurately, 
their lack of specificity. This means that these 
tests are, in general, not able to discriminate 
between different drugs or metabolites from 
the same class. On the other hand, there is 
also the possibility of a false�positive result 
deriving from the consumption of some over�
the�counter medications, which are known to 
interfere with amphetamine screenings, origi�
nating a positive result. Perhaps the term ‘pre�
sumptive positive’ would be more accurate to 
define this situation, since that sample would 
be positive, although not for drugs in the con�
firmation profile. This phenomenon is known 
as cross�reactivity, and it also occurs when the 
test cannot distinguish between chemically 
similar substances [81,133].
Despite these drawbacks, immunoas�
say techniques are the most commonly used 
methods for the screening of illicit drugs in 
biological specimens, including urine, blood 
and other matrices such as oral fluid and hair. 
This is due to the advantages that they pres�
ent over other techniques, namely that the 
sample volume needed to perform the test is 
small (usually approximately 25 µl), which 
is extremely important in oral fluid ana lysis, 
since the amount of sample available is usu�
ally limited, and there is no need for sample 
pretreatment [44].
A few studies have been published on the 
use of immunoassays for drug screening in 
oral fluid, and these concerned the detection 
of opiates [40,54,60,134], including methadone 
and its metabolite 2�ethylidene� 1,5�dimethyl�
3,3�diphenylpyrrolidine (EDDP) [135], cocaine 
and metabolites [57,136–139], cannabinoids [40] 
and amphetamines [40,140,141]. Benzodiazepines 
were also screened using this specimen [40,81] 
and, more recently, dextromethorphan [95] was 
also studied.
Special attention should be paid to the ana�
lytical challenge that the screening of highly 
potent benzodiazepines, such as flunitrazepam, 
represents in oral fluid ana lysis. Indeed, these 
compounds are usually present in the low nano�
gram range [58,86] and, therefore, often remain 
undetected by traditional enzymatic assays. This 
lack of sensitivity may be overcome by the use 
of specific immunoassays for these substances or 
their metabolites. Indeed, studies have been per�
formed on this type of assay [142], although their 
use in oral fluid ana lysis is not documented.
Immunoassay�based techniques represent 
highly sensitive and cost�effective technology; 
however, their lack of specificity makes the 
confirmation of presumptive�positive samples 
mandatory. This confirmation ana lysis is usu�
ally performed by highly specific MS�based 
methods, which are designed to identify 
unequivocally the present drug(s) and elude 
false�positive results.
The reader is referred to the review by 
Townsend et al. for a more comprehensive 
insight on immunoassay techniques, including 
biosensor technology [143].
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	n Gas chromatography–mass spectrometry
Both qualitative and quantitative toxicological 
analyses are required to be reliable, and this 
applies to all fields of analytical toxicology, 
including clinical and forensics. The hyphena�
tion of chromatographic techniques to mass 
spectrometers has brought a significant improve�
ment in drug testing in biological specimens. 
This is of particular importance in the fields 
of clinical and forensic toxicology, for which 
the needed specificity and sensitivity could be 
met [144]. 
Gas chromatography–mass spectrometry was 
the most utilized technique for the confirmation 
of a number of organic compounds back in the 
1990s, mainly due to the availability of spectral 
libraries for drugs and metabolites [145]. 
In addition, GC–MS is a very reproducible 
technique, and consistent mass spectra can be 
obtained in different laboratories, providing that 
the ionization conditions are the same (usually 
electron ionization at 70 eV). This is the reason 
why it is still the gold standard in mass detection 
specificity [146].
Gas chromatography–mass spectrometry is 
currently available in most laboratories, and this 
is still the main technique for confirmation and 
quantitation of drugs and their metabolites in 
biological specimens, including the so�called 
‘alternative’ specimens such as oral fluid, hair 
and sweat.
Analysis by GC–MS generally requires the 
extraction of the analytes from the matrix and, 
in most cases, their chemical derivatization 
in order to improve peak shape and/or allow 
chromatographic ana lysis. Typical limits of 
quantitation are in the range of approximately 
1–10 ng/ml, and the ability to achieve them 
obviously depends on the sample volume. This 
presents a limitation in terms of oral fluid, not 
only because of the low amounts at which drugs 
are present in this specimen, but also due to 
sample availability for ana lysis. For example, 
typical concentrations of 11�nor�D9�tetra�
hydrocannabinol�9�carboxylic acid in oral fluid 
are in the low picograms per milliliter range [66]. 
Analysis of these low amounts of drugs in bio�
logical matrices are, in general, impaired by 
the presence of co�extracted endogenous com�
pounds, which usually lead to an increase in 
the background noise, decreasing the analyte’s 
signal�to�noise ratio (S/N). Therefore, and to 
perform a valid quantification, the S/N must 
be increased, which can be performed using 
2D chromatography. This method is able to 
augment S/N by the selective transfer of a small 
segment of GC eluent that contains the ana�
lytes of interest to a second column coupled to a 
mass spectrometer, reducing or eliminating the 
interference of endogenous substances [67,147].
The S/N may also be increased using MS/
MS, which allow LODs of approximately 
0.01 ng/ml [66]. This type of technology was 
developed for the measurement of low�concen�
tration analytes in biological samples, including 
blood and urine. �owever, it is also extremely 
useful in those situations where sample amount 
is critical, as frequently occurs when abused 
drugs and their metabolites are analyzed in alter�
native matrices. Of particular interest is its appli�
cation to drugs that represent a more challenging 
analytical assay (e.g., cannabinoids), therefore 
requiring a MS/MS approach to achieve the 
required limits of detection. 
Another type of GC–MS/MS technology 
applicable in oral fluid ana lysis is the ion�trap 
MS. These mass spectrometers create a magnetic 
field that holds the formed ions until they are 
sequentially released to the detector. Many of 
the advantages of an ion�trap derive from being 
able to monitor ions on demand, which means 
that they can be accumulated in the trap to 
improve sensitivity. 
When the number of analytes is too big, an 
approach is to use fast GC methods, which allows 
a reduction in the time of ana lysis, maintaining 
acceptable resolution. Fast GC was developed 
following modifications on the quadrupole mass 
spectrometers, including reduced column bore 
size and more efficient capillary columns, rapid 
heating�rate ovens and high�pressure carrier gas 
control [147]. Applications include the ability to 
analyze 30 different drugs in oral fluid [49].
Several papers have been published on the use 
of GC–MS/MS for oral fluid ana lysis, including 
the detection and quantitation of several drug 
classes in this specimen. For a better understand�
ing, most of the papers published over the last 
decade are summarized in Table 1 [148–156].
	n Liquid chromatography–
mass spectrometry
Recent years have seen the development of pow�
erful technologies that have provided forensic 
scientists with new analytical capabilities that 
were unthinkable only a few years ago [157]. 
The most spectacular analytical improvement 
was the advent of LC–MS, for which there has 
been an explosion in the range of new products 
available for solving many analytical problems, 
lC–Ms
This is a highly sensitive 
analytical technique, allowing 
the detection of extremely low 
amounts of drugs in biological 
specimens
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especially for those applications aimed at ana�
lyzing nonvolatile, labile and/or high�molecu�
lar�weight compounds. In the last 10 years, an 
important step was made toward LC–MS�based 
scientific investigation. Electrospray ionization 
(ESI) and atmospheric pressure chemical ioniza�
tion (APCI) have become the most widespread 
ionization techniques [158]. 
�owever, assessing which of these ionization 
techniques is more suitable for developing a 
new procedure must be made on a case�by�case 
basis. For example, APCI is more appropriate for 
unionized analytes, and the sensitivity depends 
on the analyte structure and apparatus [144]. On 
the other hand, ESI interfaces permit MS analy�
ses of molecules in the molecular weight range of 
drugs of abuse (50–600 Da) or larger molecules, 
including proteins as large as 232 kDa [147]; this 
is the most used ionization technique.
Related to LC–MS, tandem mass spectrom�
etry (LC–MS/MS) offers superior sensitivity 
and specificity, especially if compared with the 
use of a single quadrupole. These instruments, 
when operated in the multiple reaction moni�
toring mode (MRM), allow the detection of 
extremely low levels of analytes in complex bio�
logical samples, reducing sample pretreatment 
and ana lysis time.
One limitation of LC–MS/MS, mainly in 
ESI mode, is its susceptibility to matrix effects, 
causing unwanted ion suppression or enhance�
ment [159–162]. For example, Dams et al. found 
that ESI and APCI showed matrix effects, 
with ESI being much more susceptible than 
APCI [161]. Indeed, the common and early per�
ception that utilization of LC–MS/MS practi�
cally guarantees selectivity is being challenged 
by a number of reported examples of lack of 
selectivity due to ion suppression or enhance�
ment phenomena caused by the sample matrix 
and interferences from metabolites, as well as 
‘cross�talk’ effects. 
These effects are capable of affecting ion ratios 
in the mass spectrum, potentially impairing the 
assay’s accuracy. Several strategies can be used to 
evaluate and overcome this problem, and these 
have been reviewed by Matuszewski et al. [163].
Ion�suppression effects may occur to a greater 
extent with increased solvent amount in the 
chamber. This problem can be addressed via the 
reduction of the amount of mobile phase exit�
ing the column by means of nano�LC systems, 
which will be further discussed below. Another 
possible approach is to reduce matrix constitu�
ents by reducing sample volume or adjusting 
mobile�phase composition in order to reduce co�
elution of matrix components with target ana�
lytes. In addition, matrix�matched calibrators and 
deuterated internal standards should also be used.
Another problem that LC–MS and LC–MS/
MS methods may present is the formation of 
adducts by combination with Na+, K+ or N�4+ 
introduced by the solvent in the chamber. These 
adducts produce ions of mass�to�charge ratios 
higher than expected by factors of 23, 40 or 
18 Da. In addition, these adducts do contain mul�
tiple salt ions and are capable of forming bridges 
between ions of differing masses, which will 
complicate mass spectra interpretation [164,165].
Unlike GC–MS, the development of search�
able libraries for LC–MS and LC–MS/MS is 
still a problem, since fragmentation and spectra 
differ between instruments. �owever, despite 
interinstrument reproducibility, these spectra do 
have many similar features [166,167].
Recently, two research groups have been creat�
ing homemade libraries, allowing the identifica�
tion of therapeutic agents and drugs of abuse, 
by means of the collision�induced�dissociation 
(CID) approach [168–172]. Briefly, the ions are 
accelerated and a high number of collisions are 
produced with gaseous solvent molecules, leading 
to analyte dissociation. These fragments allow the 
confirmation of the compound’s identity, and it is 
possible to design a library for each instrument. 
Liquid chromatography–MS presents a num�
ber of advantages over GC–MS, especially for 
the quantitation of more polar, termolabile or 
low�dosed drugs [144], avoiding the complicated 
and laborious derivatization procedures usually 
necessary in GC ana lysis [173,174]. Furthermore, 
these needed derivatization steps may differ for 
different compound classes according to their 
chemical structure. Indeed, for example, amphet�
amines are often derivatized by acetylation, while 
opiates originate better signals using silylating 
agents. This will pose several difficulties in the 
development of multi�analyte methods, which is 
desirable in oral fluid ana lysis, as stated earlier. 
As discussed previously, nano�LC systems 
represent a valid approach to overcome ion�sup�
pression phenomena, since the amount of sol�
vent present in the chamber is reduced, achieving 
lower limits of detection. In fact, Tomkins et al. 
reported a chip�based nanoelectrospray MS/MS 
method that could detect 0.49 ng of cotinine 
(metabolite of nicotine) in 1 ml of oral fluid [175]. 
The amount of specimen extract on the chip was 
10 µl, providing a detection limit of 4.9 pg on the 
column. Accuracy and precision results were not 
Current technologies & considerations for drug bioanalysis in oral fluid | Review
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reported and, despite the small injection volume, 
occasional specimens had reduced signal, which 
was possibly due to ion suppression from oral 
fluid interferences. 
An approach to improve laboratory through�
put and analyze a large number of analytes in 
a single run is to use ultraperformance liquid 
chromatography (UPLC) systems, which employ 
particle diameters as small as 1.5 µm and oper�
ating pressures higher than 5000 psi. �owever, 
despite having several applications in the field of 
toxicology [164,176–179], this technology has scarce 
application in oral fluid ana lysis [180].
�owever, identification of unknowns is a hard 
task for LC–MS/MS instruments. This can be 
overcome by the use of time�of�flight (TOF) 
mass spectrometers, which allow accurate mass 
measurement. This determination is performed 
by measuring flight time after acceleration in a 
vacuum tube by high voltage, and ion paths in 
the order of 2 m with flight times of 5–100 µs 
allow rapid and accurate time measurements. 
This results in short ana lysis times, accurate 
mass measurements and large dynamic ranges.
The elemental formula can be determined 
from molecular mass, and interpretation is usu�
ally unambiguous. Indeed, there are reports on 
the reduction of choices to two or three unknown 
substances using a library of 7640 compounds 
without considering LC retention times [147]. 
The application of TOF technology to oral fluid 
specimens is reported in studies such as those 
by Clauwaert et al. [79] for the determination of 
cocaine and metabolites in oral fluid, by Mortier 
et al. [61] for amphetamines, opiates and cocaine, 
and by Quintela et al. [69] for cannabinoids. 
Liquid chromatography–MS/MS�based 
methods are the state�of�the�art in analyzing 
oral fluid samples, due to the high sensitivity 
and specificity provided, and there has been a 
considerable number of published papers on the 
topic, which are summarized in Table 2.
Conclusion & future perspective
Oral fluid testing is becoming more and more 
important in analytical toxicology, namely in the 
fields of clinical and forensic toxicology. Indeed, 
sample collection is performed easily in a nonin�
vasive matter and, if necessary, under close super�
vision. This brings several advantages, including 
the cooperation of the person being analyzed and 
the difficulty in sample substitution or adultera�
tion. One of the most prominent issues concern�
ing the use of this biological specimen is that 
it can provide the ability to assess situations of 
driving under the influence of drugs, to which 
the development of easy�to�use on�site collection 
devices has contributed. Indeed, this type of 
instrument can provide a result within minutes 
of sample collection, which should be confirmed 
afterwards in laboratorial ana lysis.
This laboratorial ana lysis is only possible due 
to the huge improvement in analytical technolo�
gies seen over the last two decades, including 
both screening and confirmatory techniques. 
None of these techniques should be regarded 
as the ‘unique solution to all the problems’. On 
the contrary, these techniques complement each 
other and, currently, their use is common in 
most laboratories.
Still, analytical instruments are becoming 
more sensitive and specific, which enables both 
drug detection and quantitation in very low 
amounts, and analyses where concentrations are 
expected to be low, as occurs in oral fluid. While 
the main analytical problems are adequately 
dealt with, more investigation is needed, namely 
on the establishment of saliva�to�plasma ratios 
of several drugs, aiding result interpretation.
In general, biological matrices are complex, as 
is oral fluid. Therefore, despite the high selectiv�
ity presented by analytical instruments, it is gen�
erally mandatory that the samples are thoroughly 
cleaned�up before chromatographic ana lysis can 
be performed. In addition, ion�suppression/
enhancement effects should be comprehensively 
studied, since the precision and accuracy of the 
method may be compromised. This may be a 
problem in terms of detection limits, which rep�
resent a very important issue when analyzing oral 
fluid, since, in most situations, the amount of 
available sample is small.
No one knows what the future holds for oral 
fluid ana lysis, but it is expected that analytical 
equipment will become more sensitive and min�
iaturization will be a reality. In fact, the concept 
of a system with small specimen size, low detec�
tion limits, multiple drug testing platforms and 
high throughput is promising.
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Executive summary
Physiology & mechanisms of drug incorporation
	n Drug incorporation can occur by passive diffusion through the membrane, active processes against a concentration gradient, filtration 
through pores in the membrane and pinocytosis.
	n Drug incorporation is pH dependent.
	n Little D9-tetrahydrocannabinol (THC; main constituent of cannabis) is secreted into saliva and, therefore, the majority of THC found in 
oral fluid originates from a deposit after smoking.
	n The parent drug is the main compound detected in oral fluid, rather than its metabolites.
	n Passive contamination is possible by exposure to an environment where drugs are being consumed by others.
Collection procedures & devices
	n The collection of saliva after stimulating its production can alter drug concentrations in this specimen.
	n Saliva can be easily obtained without stimulation by spitting or the draining method.
	n The recovery of drugs from the collection devices is concentration dependent and varies according to the analyte and collection device.
	n Drug stability in the matrix should be studied, since it can affect the utility of the collection process.
Applicability of oral fluid analysis
	n Oral fluid can be used to assess an individual’s exposure to virtually every class of compounds, but drugs of abuse are by far the most 
detected substances.
	n Analytical applications of oral fluid include therapeutic drug monitoring, pharmacokinetic studies, workplace medicine and detection of 
illicit drugs in driving situations.
Analytical technologies
	n On-site collection devices
– On-site portable devices can be used for the assessment of drug-impaired driving situations. The advantages of on-site testing are 
rapid turnaround times, reduced costs and the fact that the test can be carried out virtually anywhere.
– Several studies have been conducted in the EU and USA to assess the utility of oral fluid analysis in driving situations.
	n Immunoassays
– Immunoassays are extremely useful, since they allow the saving of time and money, which would be wasted in more expensive 
confirmatory methods (usually mass spectrometric-based techniques), while most of the samples would be negative.
– Immunoassays are in general aimed at the parent compound.
– The presumptive positive samples must be confirmed by more specific techniques, namely mass spectrometric methods.
– Their poor sensitivity for low-dose compounds, such as flunitrazepam, might still be a problem.
	n Gas chromatography–mass spectrometry (GC–MS)
– GC–MS has been the most utilized technique for the confirmation of a number of organic compounds, mainly due to the availability 
of spectral libraries for drugs and metabolites.
– GC–MS is currently available in most laboratories, and this is still the main technique for confirmation and quantitation of drugs and 
their metabolites in biological specimens, including the so-called ‘alternative’ specimens, such as oral fluid, hair and sweat.
– The limits obtained when GC–MS-based techniques are used present a limitation in terms of oral fluid, mainly due to little sample 
availability for analysis.
– One possibility to overcome this problem is the use of tandem mass spectrometry.
	n Liquid chromatography–mass spectrometry (LC–MS)
– LC–MS permits the analysis of nonvolatile, labile and/or high-molecular-weight compounds.
– Electrospray ionization (ESI) and atmospheric pressure chemical ionization (APCI) have become the most widespread 
ionization techniques.
– LC–MS is highly susceptible to matrix effects (ion suppression or enhancement), and these must be assessed during method 
development and validation.
– Tandem mass spectrometry improves the detection limits.
– The use of time-of-flight mass spectrometers, which allow accurate mass measurement, allows the identification of unknowns.
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